France's Sanofi has agreed to buy U.S.-based Blueprint Medicines Corporation for up to $9.5 billion to boost its position in ...

If you're someone who needs help paying for your medicine, it's important to know that there are programs that can help lower or even eliminate the cost. Latest U.S.

Sanofi has signed an agreement to acquire US-based Blueprint Medicines to bolster its immunology pipeline with rare disease treatments.

Sanofi SNY announced that the FDA has granted orphan drug designation to its investigational drug, riliprubart, for the treatment of antibody-mediated rejection (AMR) in solid organ transplantation.

Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis (SM), a rare immunological disease, and other ...

Sanofi and Blueprint Medicines, a U.S.-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis, a rare immunological disease, and other KIT-driven diseases, have ...

Sanofi agreed to buy Blueprint Medicines Corp. for at least $9.1 billion as the French drugmaker expands further in rare immunological diseases. Sanofi will pay $129 per share in cash for the US ...

Sanofi establishesthree-year collaboration with Stanford Medicine to accelerate immunology research Projects led by collaborating researchers from the two organizations will focus on autoimmune ...

Sanofi has been an active dealmaker in the artificial intelligence space, an effort intended to beef up its capabilities in drug discovery and development. Insilico Medicine is now the latest AI ...

"Sanofi and Foundation Medicine share a commitment to new clinical solutions that address individual patient needs," said Donald A. Bergstrom, M.D., Ph.D., associate vice president and global head ...

It's too early to tell if Sanofi-Aventis's new strategic plan is the medicine the French pharma company needs after years of failing to meet expectations. But it might be enough to persuade ...

“Sanofi and Foundation Medicine share a commitment to new clinical solutions that address individual patient needs,” said Donald A. Bergstrom, M.D., Ph.D., ...